Company Overview - Protagonist Therapeutics is a clinical-stage biotechnology company focused on addressing unmet medical needs in hematology and immunology, particularly for patients with rare blood disorders and inflammatory diseases [5] - The company has a market capitalization of $5.11 billion, with a revenue of $209.22 million and a net income of $45.91 million for the trailing twelve months (TTM) [4] - Protagonist's stock experienced a significant price change of 120.48% over the past year, calculated using January 31, 2026, as the reference date [4] Recent Transaction - Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, sold 9,514 shares on January 20, 2026, for approximately $784,700, marking the largest direct open-market sale by him to date [1][6] - Post-transaction, Molina retains 97,266 shares valued at approximately $8.11 million [2] Market Sentiment - The majority of Wall Street analysts rate Protagonist Therapeutics' stock as a "strong buy," indicating positive sentiment towards the company's growth potential [6] - The company is projected to experience significant growth within the next 12-24 months, supported by partnerships with large firms like Johnson & Johnson [7][8] - Protagonist's stock soared approximately 123% in 2025, reflecting strong institutional investor support [8]